Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.
Persistent competition in key therapeutic areas, headwinds from lower COVID-19 product revenues and rising threats on the US drug pricing front are putting more pressure on new brands to deliver future growth for big pharmaceutical companies.
The industry’s first quarter sales and earnings reporting season set the stage for a year that is poised to deliver...
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.
